Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo | Latest News RSS feed

Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo - Latest News


Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

Bristol-Myers Squibb Co (NYSE:BMY) reported second-quarter earnings Thursday that topped Wall Street estimates on strong sales of its blockbuster cancer drug Opdivo and blood thinner Eliquis. For the ... read more

Bristol-Myers earnings jump 27 percent, but stock falls

Despite the beat, shares of Bristol-Myers declined in afternoon trading, while the broader markets were up, apparently because investors were disappointed by sales of its newest cancer drug, Opdivo .. ... read more

Keytruda sales power Merck to quarterly beat

(Reuters) - Drugmaker Merck & Co (MRK.N) reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer ... even with Bristol-My... read more

Looking for another news?


Bristol-Myers Squibb: The Opdivo Fiasco

BMS surprised the Street again with disappointing subgroup analysis of its important study of Opdivo in first-line non ... US equities is re-examined and reaffirmed. Bristol-Myers Squibb gets bloodied ... read more


Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

READ: Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo Shares in Merck traded flat, slightly down to US$63.84 in premarket trade. “Strong commercia... read more

Bristol Myers Squibb kidney cancer treatment meets endpoint of late-stage trial

Bristol-Myers Squibb Co. (NYSE:BMY) has announced that a late-stage trial of its Opdivo and Yervoy drugs for treating a type of kidney cancer has met one of its main end-points. The trial showed patie... read more

Bristol-Myers Squibb drops on surprise third quarter profits miss

Shares in Bristol Myers Squibb Co (NYSE ... Adjusted earnings per share for the quarter was 75 cents, below the consensus forecast of 77 cents. Strong sales of BMY’s Opdivo and Empliciti cancer drugs ... read more

Merck profit beats, but Keytruda sales fail to impress

(Reuters) - Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expec... read more

Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo

Bristol-Myers Squibb ... sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. The U.S. drugmaker, which has faced increasing competition for blockbuster Opdivo as well as pressure from a... read more

New meds help drugmakers weather strong dollar, other issues

BRISTOL-MYERS SQUIBB ... its share price. Instead, investors were disappointed by the mere $40 million in sales of Bristol's newest melanoma drug, Opdivo, part of the hot new class of immunotherapy dr... read more

New meds help drugmakers weather strong dollar, other issues

Nevertheless, Merck posted a 10-cent beat over Wall Street expectations with its adjusted ... in sales of Bristol's newest melanoma drug, Opdivo, part of the hot new class of immunotherapy drugs that ... read more

Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Faces Corruption Charges, vTv Therapeutics Flops On Debut

AMGN's adjusted earnings of $2.57 per share for the quarter also beat ... because its competitor Opdivo from Bristol-Myers Squibb has already been approved in the EU for NSCLC as well as MM. Keytruda ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us